Suprane Inhalation vapour, solution
*Company:
Baxter Holding B.V.Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 02 August 2023
File name
Suprane BE-30-03-253_12AUG19_P01.pdf
Reasons for updating
- New PIL for new product
Updated on 26 January 2023
File name
ie-spc-2019-05-suprane-clean.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 28 May 2019
File name
ie-spc-2019-05-suprane-clean.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 May 2018
File name
ie-2018-04-spc-suprane-c.docx
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 May 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 May 2017
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 4.1 - Therapeutic indications
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.1 – Removal of ‘recommended’
4.3 – changes to bullet points – add section 4.4 and change Section 4.4 to 4.1 - add text to final paragraph ‘See also Section 4.4 – Paediatric Inhalation Induction
4.4 – addition of text QT Prolongation
QT prolongation, very rarely associated with torsade de pointes, has been reported (see section 4.8). Caution should be exercised when administering desflurane to susceptible patients.
4.8 – addition of Electrocardiogram QT prolonged in Adverse Reactions table in section Cardian Disorders
Updated on 03 May 2017
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 4.1 - Therapeutic indications
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
4.1 – Removal of ‘recommended’
4.3 – changes to bullet points – add section 4.4 and change Section 4.4 to 4.1 - add text to final paragraph ‘See also Section 4.4 – Paediatric Inhalation Induction
4.4 – addition of text QT Prolongation
QT prolongation, very rarely associated with torsade de pointes, has been reported (see section 4.8). Caution should be exercised when administering desflurane to susceptible patients.
4.8 – addition of Electrocardiogram QT prolonged in Adverse Reactions table in section Cardian Disorders
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 01 September 2016
Reasons for updating
- New SPC for medicines.ie